Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

On Thursday, Reuters reported weak U.S. prescription data is contributing to investor concerns that Novo Nordisk is no longer ...

AstraZeneca on Tuesday said it had received an opinion from authorities in Shenzhen city of suspected unpaid import taxes of ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Novartis released a more optimistic full-year earnings forecast on Tuesday, citing the strong growth of drugs such as Leqvio, ...

A group of philanthropies including the Gates Foundation has set up a fund backed with nearly $500 million to help save the ...

The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide ...

LONDON, April 24 (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk (NOVOb.CO), opens new tab has raised its annual sales guidance several times a year.

Revvity reported first-quarter results above Wall Street estimates and maintained its full-year profit forecast on Monday, ...

Singapore is negotiating concessions for pharmaceutical exports to the U.S. while ensuring it still has access to high-end AI ...

Welltower forecast annual funds from operations (FFO) above estimates on Monday, betting on strong demand for the healthcare real estate investment trust's assisted living and senior housing ...